

ERRATUM

Erratum to: Modern Rheumatology Supplement (2010), S20, SY1-3

The complete abstract is given below.

The publisher and organizers sincerely apologize for the errors and regret the inconvenience they may have caused.

SY1-3

NLRP3 somatic mosaicism on “NLRP3 mutation-negative” CINCA/NOMID patients

Ryuta Nishikomori¹, Naoko Tanaka¹, Kazushi Izawa¹,
Megumu Saito², Takahiro Yasumi¹, Osamu Ohara^{3,4},
Tatsutoshi Nakahata², Toshio Heike¹

¹Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Center for iPS cell research and application (CiRA) Institute for integrated cell-material sciences, Kyoto University, Kyoto, Japan, ³Department of Human Genome Research, Kazusa DNA Research Institute, Kisarazu, Japan,

⁴Laboratory for Immunogenomics, RIKEN Research Center for Allergy and Immunology, RIKEN Yokohama Institute, Yokohama, Japan

CINCA syndrome/NOMID is an autoinflammatory disease whose triad consists of urticarial rash, arthritis/arthropathy, CNS symptoms due to chronic aseptic meningitis. NLRP3 gene has been reported as a responsible gene for the syndrome and the reported mutations are on the coding regions, especially missense mutations on exons 3, 4 and 6. The molecular mechanism underlying the CINCA/NOMID is believed to be dysregulated NLRP3 inflammatory activation by the NLRP3 mutations. Although the molecular mechanism is uncovered, it has been known that approximately 40% of CINCA/NOMID patients lack NLRP3 mutations on its coding regions, which suggests other genes mutations or NLRP3 non-coding regions mutations could be involved in these patients. We have recently reported NLRP3 somatic mosaicism occurs on some, but not all of the “NLRP3 mutation-negative” CINCA/NOMID patients (Saito, Blood 2008). We extended our study worldwide by collaborating with the researchers working on CINCA/NOMID (US, France, the Netherlands, Spain, Italy). Now we are analyzing the NLRP3 somatic mosaicism by subcloning-based strategy. I am going to talk about “NLRP3 mutation-negative” CINCA/NOMID and on-going study on these patients world-wide.